Welcome to our dedicated page for Cerevel Therapeutics Hldng news (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Hldng stock.
This page provides a historical news archive for Cerevel Therapeutics Holdings, Inc. (formerly Nasdaq: CERE), a neuroscience-focused biopharmaceutical company that became part of AbbVie following the completion of an acquisition announced by AbbVie on August 1, 2024. Before the transaction, Cerevel regularly issued updates on its clinical pipeline, corporate strategy and capital raising activities.
News items for Cerevel include detailed announcements on its key investigational therapies such as emraclidine, tavapadon, darigabat, CVL-871 and CVL-354. These releases cover topics like Phase 2 and Phase 3 trial designs, topline clinical results, regulatory designations and development plans in schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder, Parkinson’s disease, mood disorders and related neuroscience indications. For example, Cerevel announced positive topline results from the pivotal Phase 3 TEMPO-3 adjunctive trial of tavapadon in people living with Parkinson’s disease.
Investors and researchers can also review historical corporate and financial communications, including quarterly financial results, business updates, investor webcasts, and the October 2023 public offering of common stock that Cerevel stated would support operations and planned data readouts. In addition, the archive reflects transaction-related news, such as the December 6, 2023 joint announcement by AbbVie and Cerevel of a definitive acquisition agreement, and subsequent commentary from law firms examining the terms of the merger.
Although CERE shares are no longer expected to trade following the closing of the AbbVie acquisition, this news history remains useful for understanding how Cerevel’s neuroscience programs evolved, how management communicated clinical milestones, and how the acquisition rationale was framed by AbbVie. Users interested in ongoing development of these assets should consult AbbVie’s current disclosures, while using this page as a record of Cerevel’s standalone public-company era.
Cerevel Therapeutics (Nasdaq: CERE) announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022. CEO Tony Coles will take part in a fireside chat at 9:20 AM ET. Investors can access the live webcast via the company's website, with a replay available afterward. Cerevel, based in Cambridge, specializes in neuroscience diseases and has a diversified pipeline, including five clinical-stage therapies for conditions such as Parkinson’s and schizophrenia.
Cerevel Therapeutics Holdings, Inc. (CERE) announced the pricing of a public offering of 7,250,000 shares at $35.00 per share, raising approximately $253.8 million. The offering is set to close on August 16, 2022. Additionally, Cerevel priced $300 million in convertible senior notes due 2027 in a concurrent private placement. Net proceeds from both offerings are expected to support the development of emraclidine and other pipeline programs, with $238.3 million estimated from common stock and $291.1 million from the notes.
Cerevel Therapeutics has priced a private offering of $300 million in 2.50% convertible senior notes due 2027, with an additional $45 million option for buyers. The notes, offering a conversion rate of 21.5633 shares per $1,000 principal, will mature on August 15, 2027, with semi-annual interest payments starting February 15, 2023. Concurrently, Cerevel is offering 7,250,000 shares of common stock at $35 per share, expecting net proceeds of approximately $238.3 million. Proceeds from both offerings will support the development of emraclidine and its pipeline programs.
Cerevel Therapeutics Holdings has announced a public offering of $250 million in common stock, with a potential additional $37.5 million available through underwriters. Concurrently, the company will offer $250 million in convertible senior notes due 2027. Cerevel plans to use the proceeds for the development of emraclidine and other programs, including pre-commercial planning for tavapadon. The offering is subject to market conditions, and all shares in the stock offering will be sold by Cerevel.
Cerevel Therapeutics announced a private offering of $250 million in convertible senior notes due 2027 to qualified institutional buyers. The offering includes an option for purchasers to buy an additional $37.5 million. Interest will be payable semi-annually, and noteholders can convert notes into cash or shares. Concurrently, Cerevel is offering $250 million in common stock with a similar option for underwriters. Proceeds will support the development of emraclidine and other pipeline programs, as well as general corporate purposes.
Cerevel Therapeutics reported its Q2 2022 financial results and provided updates on its pipeline, emphasizing a commitment to neuroscience therapies. The company has initiated two Phase 2 trials for emraclidine in schizophrenia, with data expected in 1H 2024. Cerevel maintains a healthy cash position of $531M, projected to support operations through 2024. Additionally, the company is advancing its drug candidates, including darigabat for epilepsy and panic disorder, and tavapadon for Parkinson’s disease. The total R&D expenditure significantly rose to $72.5M for Q2.
Cerevel Therapeutics (Nasdaq: CERE) announced it will release its second quarter 2022 financial results on August 1, 2022, before the U.S. markets open. A conference call will follow at 8:00 a.m. ET, where management will discuss the results and recent business updates. Investors can register for the call via a provided link. Cerevel, focused on neuroscience disease treatments, has a pipeline that includes five clinical-stage therapies for conditions like Parkinson’s and schizophrenia.
Cerevel Therapeutics (Nasdaq: CERE) has appointed Suneet Varma as a new board member, succeeding Morris Birnbaum, who is retiring. Varma, currently Global President of Rare Diseases at Pfizer, brings extensive experience in commercial success and leadership. He aims to support Cerevel’s mission to advance treatments for neuroscience diseases. Dr. Birnbaum, a founding board member since 2018, significantly contributed to the company’s progress. The leadership change is expected to enhance Cerevel's capabilities in tackling complex neurological conditions.
Cerevel Therapeutics, listed on Nasdaq under the ticker CERE, announced that its chairperson and CEO, Tony Coles, M.D., will speak at the Jefferies Healthcare Conference on June 8, 2022, at 10:30 am ET. The event will feature a live webcast available on the company's investor relations page, with a replay accessible after the event.
The company, focused on neuroscience diseases, has a pipeline of five clinical-stage therapies targeting conditions such as Parkinson's and schizophrenia. For more details, visit www.cerevel.com.
Cerevel Therapeutics (CERE) reported a strong cash position of $550.9 million as of March 31, 2022, bolstered by a $37.5 million risk-sharing arrangement in April 2022. The company is on track to initiate two Phase 2 trials for emraclidine in schizophrenia by mid-2022, with results expected in the first half of 2024. Positive results from the darigabat Phase 1 trial were announced, and data from its Phase 2 epilepsy trial is now anticipated in mid-2023. R&D expenses rose to $55.0 million in Q1 2022, reflecting ongoing clinical advancements.